drugset / Trial / NCT04624854
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
Phase 4
Completed
8250 enrolled
Harbin Medical University
Chinese Society of Cardiology · collabLepu Medical Technology (Beijing) Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least 12 months after being implanted with a drug-eluting stent (DES) at one of 100 different centers. All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a permuted completely randomization.
Timeline
- Start
- 2020-10-28
- Primary completion
- 2025-09-23
- Completion
- 2025-09-23
Publications
- Tian J, Wang Z, Wang Y, Wang F, Peng X, Xiao J, Li C, Hou X, Tong Q, Yu X, Gao G, Zhao P, Zhao J, Liu Y, Qin Z, Lu H, Zhang S, Li S, Weng Z, Tang H, He Y, Zhang C, Liu Y, Jiang J, Zhang J, Cai L, Xiu L, Mintz GS, Wang D, Stone GW, Yu B; DAPT-MVD Trial Investigators. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. N Engl J Med. 2026 Jul 16;395(3):233-242. doi: 10.1056/NEJMoa2517588.
- Tian J, Wang Z, Wang Y, Wang F, Wang Y, Zhao P, Hou X, Peng X, Tian M, Wang D, Yu B. Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial. Clin Cardiol. 2024 Dec;47(12):e70049. doi: 10.1002/clc.70049.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Comparator | Aspirin | Small molecule | 75 mg | — |
| Comparator | Aspirin | Small molecule | 150 mg | — |